Metabolic impact of low dose IL-2 therapy for primary Sjogren's Syndrome in a double-blind, randomized clinical trial. Feng R, Xiao X, Wang Y, Huang B, et al. Clin Rheumatol 2024;43:3789-3798.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Feng R, Xiao X, Wang Y, Huang B, et al. Metabolic impact of low dose IL-2 therapy for primary Sjogren's Syndrome in a double-blind, randomized clinical trial. Clin Rheumatol 2024;43:3789-3798.
PMID: 39482484